Key Inclusion Criteria:

          1. Histologically or cytologically documented locally advanced or recurrent non-small
             cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive
             radiotherapy with or without chemoradiotherapy, or metastatic-nonsquamous or squamous
             NSCLC.

          2. No prior systemic treatment for metastatic NSCLC.

          3. Agreement to provide archival tissue (formalin-fixed paraffin-embedded block
             containing tumor [preferred] or 6 to 15 freshly cut unstained slides) or fresh biopsy
             (if archival tissue is not available) for prospective central evaluation of programmed
             cell death ligand-1 (PD-L1) levels and retrospective analysis of other biomarkers.

          4. Tumors with PD-L1 tumor cell ≥ 50% expression as centrally determined.

          5. At least 1 measurable lesion as defined per RECIST v1.1.

        Key Exclusion Criteria:

          1. Known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or an
             anaplastic lymphoma kinase fusion oncogene.

          2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand
             (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or
             any other antibody or drug specifically targeting T-cell costimulation or checkpoint
             pathways.

          3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.

          4. Active autoimmune diseases or history of autoimmune diseases that may relapse.

          5. Any active malignancy ≤ 2 years before randomization except for the specific cancer
             under investigation in this study and any locally recurring cancer that has been
             treated curatively (for example, resected basal or squamous cell skin cancer,
             superficial bladder cancer, carcinoma in situ of the cervix or breast).

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.